% of Participants Achieving ≥2- and ≥3-Line Near Vision Improvement1,2
Day 1, CLARITY 2, full analysis set (VIZZ: n=77; vehicle: n=76). 3-line vehicle 5%-12%, 2-line vehicle 17%-24%. CLARITY 2 trial: Near visual acuity was assessed at 40cm using monocular DCNVA (distance-corrected near visual acuity). CLARITY was a Phase 3, multicenter, double-masked, randomized, controlled efficacy and safety study of VIZZ (1.44% aceclidine) for the treatment of presbyopia. The primary efficacy endpoint was the percentage of patients who achieved ≥3 lines of improvement in DCNVA without losing 1 line (5 letters) or more of distance vision at 3 hours post treatment on Day 1. VIZZ achieved all primary and secondary endpoints (in all cases, P<0.0001).¹,²
Patients may experience dim or dark vision. Dim vision was reported in 16% of study participants.